Until 2006 doing business as Viral Therapeutics,Vybion is a development stage Company with proprietary technologies for Intrabody development currently pursuing strategies to treat neurodegenerative diseases such as Huntington's, SBMA and SCA1, 3, 7 and Alzheimer's. The firm develops human monoclonal antibody drugs: HIV peptide mimetics with NIH funding, as well as provides recombinant proteins as reagents, therapeutic targets, diagnostics, and therapeutic proteins. The company also provides contract biopharmaceutical development services offering drugs for diabetes, inflammatory disease, autoimmune disease, cancer, and various other therapeutic areas. The company provides recombinant proteins for therapeutic and diagnostic applications and develops CoFab for acute care. ProCode is the only antibody platform capable of selecting Intrabodies that are soluble, expressible and functional in the cellular cytoplasm immediately upon selection. Intrabodies can target protein-protein interactions, phosphorylation and other novel interactions exclusive to signal transduction. Intrabodies can validate drug targets and function as drugs to treat a wide range of diseases such as cancer, chronic and acute inflammatory disease, infectious disease and autoimmune disease. Preclinical programs include Huntington's, ALS other neurodegenerative diseases as well as insulin resistant diabetes. In December 2018, Vybion Inc. was granted by the US Food and Drug Administration (FDA) orphan drug designation for INT41, the Companyâ¢'s Intrabody delivered with AAV for the treatment of Huntington's disease. Orphan designation is granted by the FDA Office of Orphan Products Development to advance the evaluation and development of safe and effective therapies for the treatment of rare diseases or conditions affecting fewer than 200,000 people in the U.S
